Skip to main content
. 2017 Nov 9;8(63):107134–107148. doi: 10.18632/oncotarget.22359

Figure 4. miR-1271 directly targets DDIT3.

Figure 4

(A) Prediction of DDIT3-targeting sites of miR-1271 using miRanda. (B) Immunoblotting analysis of DDIT3 level in various BCa cells. 48 h after transfection, ostensible MCF7 cells, untreated MCF7/LR cells, MCF7/LR cells with mimic NC transfection, and MCF7/LR cells with miR-1271 mimic transfection were subjected to immunoblotting (C) or RT-qPCR (D) analyses of DDIT3 level. 48 h after transfection with miR-1271 inhibitor or Anti-NC, MCF7 cells were subjected to immunoblotting (E) or RT-qPCR (F) analyses of DDIT3 level. (G) schematic diagram showing the mutation of miR-1271 binding site in the DDIT3 3’UTR. (H) Relative luciferase activity was analyzed after wild-type or mutant 3’UTR reporter plasmids were co-transfected with different plasmids in COS-1 cells.